Bulk Pharmaceutical API Sources for METRIZAMIDE

Bulk Pharmaceutical API Sources for METRIZAMIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		Y`X\AL@BFBgHlaieko`JqRllkLbbbbbbRaTljbbbJwFfqtDQTTtsUUUTUETu}Vt]@@
NovoSeek		443944
MolPort		MolPort-000-698-998
ABI Chem		AC1L9FG6

Bulk Active Pharmaceutical Ingredient (API) Sources for Metrizamide: A Strategic Overview

Last updated: July 30, 2025

Introduction

Metrizamide, a non-ionic iodinated contrast agent, has historically played a vital role in neuroimaging and diagnostic radiology due to its ability to enhance brain imaging. It belongs to the class of high-density contrast media utilized primarily in myelography, cerebrospinal fluid (CSF) imaging, and angiography. As demand for contrast agents evolves amid regulatory shifts and geopolitical factors, understanding the landscape of bulk API sourcing—including manufacturing origins, supplier profiles, and supply chain integrity—is essential for stakeholders in pharmaceutical development, distribution, and healthcare procurement.

This article examines the current state of bulk API sources for metrizamide, analyzing manufacturing regions, supplier credibility, regulatory considerations, and supply stability to inform strategic procurement decisions.

Chemical and Manufacturing Profile of Metrizamide API

Metrizamide's active pharmaceutical ingredient (API) is chemically known as Amipaque or Metrizamide, with its chemical structure classified as a non-ionic, water-soluble iodinated contrast agent. Its synthesis involves multi-step chemical reactions, primarily in specialized pharmaceutical manufacturing facilities adhering to strict Good Manufacturing Practice (GMP) standards.

The API's sourcing hinges on high-purity manufacturing, regulatory compliance, and capacity to meet global demand. Historically, key manufacturing hubs include European, Asian, and North American regions, with some companies outsourcing production to countries with advanced chemical manufacturing infrastructures, such as India and China.

Primary Sources of Metrizamide API

1. European Manufacturers

Europe has been a traditional center for high-end pharmaceutical chemical synthesis, hosting several reputed API producers specializing in contrast media agents.

• Bayer AG (Germany): Historically, Bayer developed and supplied high-purity APIs, including contrast media precursors. Their expertise in chemical synthesis and regulatory oversight makes European sources highly credible, although Bayer's focus has shifted towards finished pharmaceuticals rather than bulk APIs in recent years.

• Serono (Switzerland): Known for radiocontrast agents, Serono's legacy includes manufacturing APIs for contrast media. While some operations have been integrated into Merck KGaA, legacy facilities may still produce bulk APIs under specific licensing agreements.

2. Asian Manufacturers

Asia has become prominent in bulk pharmaceutical ingredient manufacturing, driven by cost efficiencies, improved regulatory compliance, and expanding capacity.

• India: India’s chemical and pharmaceutical sectors boast numerous API manufacturers capable of producing metrizamide with GMP certification. Notable companies include Biocon, Mylan, and Sun Pharma, although their focus on contrast media APIs varies. Indian companies such as Gufic Biosciences and Apex Engineering have capacities for iodinated contrast media APIs.

• China: Chinese pharmaceutical manufacturers have increased their API production capabilities. Companies such as North China Pharmaceutical Group Corporation (NCPC) and Qilu Pharmaceutical are engaged in contrast media synthesis, often exporting APIs internationally.

3. North American Suppliers

North American suppliers, particularly within the United States and Canada, typically manufacture APIs for domestic use, often with stringent regulatory standards.

• GE Healthcare (now part of Danaher): While primarily a provider of contrast media finished products, some API synthesis occurs here with high regulatory oversight.

• Contract Manufacturing Organizations (CMOs): Several US-based CMOs, such as Patheon and Fujifilm Diosynth Biotechnologies, execute custom API manufacturing, including contrast agents, under GMP conditions.

Supply Chain Considerations

Regulatory Compliance: Sourcing from regions with strict GMP enforcement minimizes risks of substandard API quality, crucial for safety and efficacy.

Quality Certifications: ISO certifications, FDA and EMA approvals, and validation reports are essential for verifying supplier credibility.

Capacity and Lead Time: Given the bulk demand for contrast agents, suppliers with scalable manufacturing and reliable supply chains are preferable.

Trade and Political Risks: The geopolitical landscape influences supply stability. Tariffs, export restrictions, and diplomatic relations can impact API availability, especially from China and India.

Intellectual Property and Licensing: Ensuring licensing agreements and IP rights are compliant reduces legal and regulatory exposure.

Current Market Dynamics and Challenges

• Regulatory Shifts: The European Medicines Agency (EMA) and FDA increasingly scrutinize iodinated contrast agents due to safety concerns. Manufacturers must adapt to evolving standards, affecting API production.

• Supplier Consolidation: Market consolidation has led to fewer API suppliers capable of producing high-purity metrizamide APIs, potentially impacting pricing and supply security.

• COVID-19 Pandemic Impact: Disruptions in supply chains and manufacturing shutdowns have occasionally caused shortages of contrast media APIs.

• Environmental and Sustainability Concerns: Manufacturing processes involving iodinated compounds pose environmental challenges. Suppliers investing in sustainable processes may have a competitive advantage.

Emerging Trends and Strategic Implications

• Shift towards Synthetic and Biosynthetic Alternatives: Development of alternative contrast agents may influence demand for metrizamide APIs, prompting manufacturers to diversify portfolios.

• Regional Diversification: Brands seek diversified supply sources to mitigate risks. Emerging markets like Southeast Asia are gradually expanding their API manufacturing footprints.

• Regulatory Harmonization: Increased global harmonization of GMP standards simplifies sourcing from international suppliers, facilitating reliable procurement.

Conclusion

The landscape for bulk API sourcing for metrizamide is characterized by a combination of traditional European manufacturing and expanding Asian capacity. While Europe maintains high-quality standards, Asian suppliers offer cost-effective and scalable options, with India and China emerging as key players. Ensuring regulatory compliance, quality assurance, and supply chain resilience remains critical for procurement strategies.

Key Takeaways

• European manufacturers historically provided high-purity APIs but are less active due to shifting focus to finished drugs.

• India and China serve as primary alternative sources, offering competitive pricing and substantial manufacturing capacity.

• Due diligence on supplier certifications, quality metrics, and regulatory adherence is vital.

• Supply chain resilience can be enhanced through diversification and building relationships with multiple reputable suppliers.

• Emerging environmental standards and regulatory guidelines will influence future API manufacturing and sourcing decisions.

FAQs

1. Are there fully licensed, GMP-certified API producers for metrizamide in China and India?
Yes, several manufacturers in China and India operate under GMP standards and have obtained licenses recognized by regulatory agencies such as the FDA and EMA. However, procuring from highly reputable, certified suppliers is essential to ensure quality.

2. What regulatory hurdles affect sourcing APIs from Asian countries?
Regulatory hurdles include ensuring compliance with GMP standards, export/import restrictions, and verifying proper certification documentation. Additionally, language barriers and differing regulatory frameworks require diligent oversight.

3. How does supply chain disruption impact the availability of metrizamide API?
Disruptions from geopolitical tensions, pandemics, or environmental concerns can cause shortages. Diversifying sourcing and maintaining buffer inventories mitigate risks.

4. What role do contract manufacturing organizations play in the metrizamide API supply chain?
CMOs enable flexibility, capacity expansion, and compliance management, serving as reliable partners for API synthesis when aligned with strict quality standards.

5. Will the demand for metrizamide API decrease with newer imaging contrast agents?
Potentially. Although some replaced by safer alternatives, metrizamide remains relevant in specific diagnostic procedures. Its continued use depends on regulatory approval and clinical preferences, influencing API sourcing strategies.

---

Sources:
[1] European Pharmacopoeia, 10th Edition.
[2] U.S. FDA Drug Master Files and Certificates of Suitability.
[3] Global Data: Pharmaceutical API Market Analysis.
[4] Company Annual Reports and Regulatory Filings.
[5] Industry Reports on Contrast Media API Manufacturing.